Levista-M Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, formulated for the effective management of allergic conditions. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby alleviating symptoms such as sneezing, rhinorrhea, nasal congestion, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors (CysLT1), reducing airway inflammation, bronchoconstriction, and mucus production, which are common in asthma and allergic rhinitis. The synergistic action of these agents provides comprehensive relief from both upper and lower respiratory allergic symptoms. Levista-M is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct in the management of asthma to improve symptom control and reduce exacerbations. The tablet is administered orally, typically once daily, with or without food, as directed by a healthcare professional. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with known hypersensitivity to either component. Common adverse effects may include headache, fatigue, and gastrointestinal disturbances. Levista-M offers a convenient and effective therapeutic option for patients requiring combined antihistaminic and leukotriene receptor antagonist therapy.